Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to determine the safety and efficacy of a novel combination of agents, enzalutamide and everolimus, for the treatment of patients with metastatic castrate-resistant prostate cancer who have never received prior chemotherapy, or who have previously received docetaxel chemotherapy and have progressive disease.
Epistemonikos ID: d1cbf54067e0b19a2c7311b4675c4c7e6563ec99
First added on: May 11, 2024